Genprex Inc

GNPX

Company Profile

  • Business description

    Genprex Inc is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Its technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex's oncology program utilizes its systemic, non-viral Oncoprex Delivery System, which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The company's product candidate, Reqorsa Gene Therapy (quaratusugene ozeplasmid), is initially being developed in combination with prominent, approved cancer drugs to treat Non-Small Cell Lung Cancer (NSCLC) and Small Cell Lung Cancer (SCLC).

  • Contact

    3300 Bee Cave Road
    Suite 650-227
    AustinTX78746
    USA

    T: +1 877 774-4679

    https://www.genprex.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2026

    Employees

    13

Stocks News & Analysis

stocks

Higher distribution from ASX income share

Solid long-term outlook.
stocks

Are ASX REITs the better way to own property?

Cheap valuations, strong yields and a changing Aussie property landscape.
stocks

Cheap Dividend Aristocrat has Fair Value raised after earnings

Dividend forecasts raised after balance sheet regains strength.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries9,279.003.00-0.03%
CAC 408,628.658.14-0.09%
DAX 4026,434.875.44-0.02%
Dow JONES (US)53,732.41107.58-0.20%
FTSE 10010,766.6616.550.15%
HKSE25,453.23336.381.34%
NASDAQ26,729.1673.86-0.28%
Nikkei 22569,220.25506.450.74%
NZX 50 Index13,721.98132.40-0.96%
S&P 5007,785.7613.23-0.17%
S&P/ASX 2009,073.206.10-0.07%
SSE Composite Index3,982.6555.481.41%

Market Movers